オノ　マサフミ   ONO Masafumi   小野　正文    所属   医学部 医学科（附属足立医療センター）    職種   非常勤講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice.
掲載誌名	正式名：Journal of gastroenterology 略　 称：J Gastroenterol ISSNコード：14355922/09441174
掲載区分	国内
巻・号・頁	49(6),pp.1065-73
著者・共著者	Ono Masafumi, Ogasawara Mitsunari, Hirose Akira, Mogami Sachiko, Ootake Nobuhiro, Aritake Kosuke, Higuchi Takuma, Okamoto Nobuto, Sakamoto Shuji, Yamamoto Masahiro, Urade Yoshihiro, Saibara Toshiji, Oben Jude A
発行年月	2014/06
概要	BACKGROUND:Obesity-induced liver disease (nonalcoholic fatty liver disease, NAFLD) is now the commonest cause of chronic liver disease in affluent nations. There are presently no proven treatments for NAFLD or its more severe stage, nonalcoholic steatohepatitis (NASH). Bofutsushosan (BTS), a Japanese herbal (Kampo) medicine, long used as an anti-obesity medicine in Japan and other Asian countries, has been shown to reduce body weight and improve insulin resistance (IR) and hepatic steatosis. The precise mechanism of action of BTS, however, remains unclear. To evaluate the ability of BTS to prevent the development of NASH, and determine the mediators and pathways involved.METHODS:C57BL/6 mice were injected intra-peritoneally with gold-thioglucose and fed a high-fat diet (HF) or HF diet admixed with either 2 or 5 % BTS for 12 weeks. The effectiveness of BTS in attenuating features of NASH and the mechanisms through which BTS attenuated NASH were then assayed through an assessment of the anthropometric, radiological, biochemical and histological parameters.RESULTS:BTS attenuated the progression of NASH through induction of adiponectin and its receptors along with an induction of PPAR-α and PPAR-γ, decreased expression of SREBP-1c, increased hepatic fatty acid oxidation and increased hepatic export of triglycerides. BTS moreover, reduced IR through phosphorylation of the protein kinase, Akt.CONCLUSIONS:BTS through induction of adiponectin signaling and Akt attenuated development of NASH. Identification of the active entity in BTS should allow development of novel treatments for NASH.
DOI	10.1007/s00535-013-0852-8
PMID	23800945